Kyowa Kirin Reports Three-Year Real-World Data On Burosumab In Adults With XLH

Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co., Ltd., announced publication of three-year real-world findings comparing burosumab with oral phosphate and active vitamin D (Pi/D) in adults with X-linked hypophosphatemia. The provided article text is truncated before reporting the findings, so no outcome or treatment comparison can be assessed.